36093-99-9

Usage

Uses

Used in Pharmaceutical Research:
[2-(4-CHLORO-PHENYL)-THIAZOL-4-YL]-METHANOL is used as a chemical intermediate for the development of new pharmaceutical compounds. Its unique structure allows it to be a potential building block in the synthesis of novel drugs, particularly those targeting specific biological pathways or receptors.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, [2-(4-CHLORO-PHENYL)-THIAZOL-4-YL]-METHANOL is utilized as a key component in the design and synthesis of therapeutic agents. Its presence of a thiazole ring and a chloro-phenyl group can contribute to the compound's interaction with biological targets, making it a valuable asset in the creation of new medications.
Used in Organic Synthesis:
[2-(4-CHLORO-PHENYL)-THIAZOL-4-YL]-METHANOL is employed as a versatile reagent in organic synthesis. Its functional groups and structural features facilitate its use in a variety of chemical reactions, enabling the production of a wide range of organic compounds for various applications.
Used in Chemical Research:
In chemical research, [2-(4-CHLORO-PHENYL)-THIAZOL-4-YL]-METHANOL serves as a subject of study to understand its properties, reactivity, and potential applications. Researchers explore its behavior in different chemical environments to uncover new insights and applications in the broader field of chemistry.
Used in Drug Development:
[2-(4-CHLORO-PHENYL)-THIAZOL-4-YL]-METHANOL is used as a precursor in the development of new drugs. Its unique chemical structure may offer advantages in terms of selectivity, potency, or pharmacokinetics, making it a valuable component in the creation of innovative therapeutic agents.
Used in Chemical Synthesis Industry:
Within the chemical synthesis industry, [2-(4-CHLORO-PHENYL)-THIAZOL-4-YL]-METHANOL is utilized as a key reactant in the synthesis of complex organic molecules. Its presence of a thiazole ring and a chloro-phenyl group provides opportunities for further functionalization and the creation of a diverse array of chemical products.

Upstream product

• 61786-00-3 ethyl 2-(4-chlorophenyl)thiazole-4-carboxylate 
• 623-03-0 4-Cyanochlorobenzene 
• 17969-22-1 4-chloromethyl-2-(4-chloro-phenyl)-thiazole 
• 21278-77-3 2-(4-chlorophenyl)thiazole-4-carbaldehyde 
• 40361-62-4 4-chloromethyl-2-(4-chloro-phenyl)-4,5-dihydro-thiazol-4-ol 
• 2521-24-6 4-chlorothiobenzamide 

Downstream Products

• 52041-83-5 [5-bromo-2-(4-chloro-phenyl)-thiazol-4-yl]-methanol 
• 52041-97-1 5-bromo-2-(4-chloro-phenyl)-thiazole-4-carboxylic acid 
• 17228-98-7 2-(4-chlorophenyl)thiazole-4-carboxylic acid 
• 52041-93-7 5-bromo-2-(4-chloro-phenyl)-thiazole-4-carbaldehyde 
• 1163175-95-8 2-{[2-(4-Chlorophenyl)-1,3-thiazol-4-yl]methoxy}-4-[4-(2-hydroxyethoxy)phenyl]-5-oxo-5,6-dihydro-1,6-naphthyridine-3-carbonitrile 
• 1244030-74-7 2-amino-3-cyano-4-[2-(4-chlorophenyl)thiazol-4-yl]-7-(dimethylamino)-4H-chromene 
• 17969-22-1 4-chloromethyl-2-(4-chloro-phenyl)-thiazole 
• 21278-78-4 1-((2-(4-chlorophenyl)thiazol-4-yl)methylene)thiosemicarbazide 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of novel thiazole-derivatives as mitochondrial targeting inhibitors of cancer cells

Mitochondria are pivotal energy production sources for cells to maintain necessary metabolism activities. Targeting dysfunctional mitochondrial features has been a hotspot for mitochondrial-related disease researches. Investigation with cancerous mitochondrial metabolism is a continuing concern within tumor therapy. Herein, we set out to assess the anti-cancer activities of a novel family of TPP-thiazole derivatives based on our earlier research on mitochondrial targeting agents. Specifically, we designed and synthesized a series of TPP-thiazole derivatives and revealed by the MTT assay that most synthesized compounds effectively inhibited three cancer cell lines (HeLa, PC3 and MCF-7). After structure modifications, we explored the SAR relationships and identified the most promising compound R13 (IC50 of 5.52 μM) for further investigation. In the meantime, we performed ATP production assay to assess the selected compounds inhibitory effect on HeLa cells energy production. The results displayed the test compounds significantly restrained ATP production of cancer cells. Overall, we have designed and synthesized a series of compounds which exhibited significant cytotoxicity against cancer cells and effectively inhibited mitochondrial energy production.

Synthesis of new 2-(thiazol-4-yl)thiazolidin-4-one derivatives as potential anti-mycobacterial agents

To search for potent antimycobacterial lead compounds, a new series of 3-substituted phenyl-2-(2-(substituted phenyl)thiazol-4-yl) thiazolidin-4-one (5a-t) derivatives have been synthesized by the condensation of 2-substituted phenyl thiazole-4-carbaldehy

Synthesis and biological evaluation of new 2-aryl-4-((4-aryl-1H-1,2,3-triazol-1-yl)methyl)thiazole derivatives

A series of 2-aryl-4-((4-aryl-1H-1,2,3-triazol-1-yl)methyl)thiazole derivatives (8a–p) have been synthesized. The structure of the newly synthesized compounds was determined by spectral analysis. The title compounds were screened for their preliminary ant

Synthesis, antitubercular and antimicrobial potential of some new thiazole substituted thiosemicarbazide derivatives

The increase in antibiotic resistance due to multiple factors has warranted the need for search of new compounds which are active against multidrug resistant pathogens. In this context a small focused library of thiosemicarbazide derivatives of 2-arylthiazole-4-carbaldehyde, 4-methyl-2-arylthiazole-5-carbaldehyde and 1-(4-methyl-2-arylthiazol-5-yl) ethanone, (5a–l) has been synthesized. The title compounds were screened for inhibitory activity against Mycobacterium tuberculosis H37Ra (ATCC 25177) and Mycobacterium bovis Bacille Calmette Guerin (ATCC 35743) strains. The synthesized compounds, 5a–l were further assayed for their cytotoxic activity against the two human cancer cell lines, HeLa and human colon carcinoma 116 cell lines and showed no significant cytotoxic activity against these two cell lines at the maximum concentration evaluated. Further, the synthesized compounds were found to have potential antibacterial activity against Gram-negative bacteria, Escherichia coli, Pseudomonas flurescence and Gram-positive bacteria, Staphylococcus aureus, Bacillus subtilis. Most of the synthesized compounds showed moderate activity against fungal strain Candida albicans. This study provides valuable directions to our ongoing endeavor of rationally designing more potent antimycobacterial agent.

Discovery of the disubstituted oxazole analogues as a novel class anti-tuberculotic agents against MDR- and XDR-MTB

A high-throughput screening effort on 45,000 compounds resulted in the discovery of a disubstituted oxazole as a new structural class inhibitor of Mycobacterium tuberculosis (Mtb). In order to improve the activity and investigate the SAR of this scaffold, a series of disubstituted azole analogues have been designed and synthesized. The newly synthesized compounds 1a-y were evaluated for their in vitro anti-TB activity versus replicating, multi- and extensive drug resistant Mtb strains. All the compounds, except 1o, 1p and 1q, showed potent anti-TB activity with MIC of 1-64 mg/L. The test of broad spectrum panel revealed that this series are specific to Mtb. The cytotoxicity assessment indicated that the compounds were not cytotoxic against HEK 293 cells. The compounds could have a novel mechanism to anti-Mtb as they can inhibit drug sensitive and drug resistant Mtb.

Synthesis and in-vitro cytotoxicity of poly-functionalized 4-(2-arylthiazol-4-yl)-4H-chromenes

A new series of 4-aryl-4H-chromenes bearing a 2-arylthiazol-4-yl moiety at the 4-position were prepared as potential cytotoxic agents. The in-vitro cytotoxic activity of the synthesized 4-aryl-4H-chromenes was investigated in comparison with etoposide, a well-known anticancer drug, using MTT colorimetric assay. Among them, the 2-(2-chlorophenyl)thiazol-4-yl analog 4b showed the most potent activity against nasopharyngeal epidermoid carcinoma KB, medulloblastoma DAOY, and astrocytoma 1321N1, and compound 4d bearing a 2-(4-chlorophenyl) thiazol-4-yl moiety at the 4-position of the chromene ring exhibited the best inhibitory activity against breast cancer cells MCF-7, lung cancer cells A549, and colon adenocarcinoma cells SW480 with IC50 values less than 5 μM. The ability of compound 4b to induce apoptosis was confirmed in a nuclear morphological assay by DAPI staining in the KB and MCF-7 cells.

Synthesis of new 1,4-dihydropyridine derivatives containing thiazolyl substituents

A series of 4-[2-methyl (or aryl) thiazole-4-yl]-2,6-dimethyl-3,5-diacetyl (or dibenzoyl) 1,4-dihydropyridines were synthesized using a modified Hantzsch reaction involving the condensation of the corresponding aldehyde with acetyl acetone or benzoyl acetone. The preparation of the corresponding aldehydes (2-methylthiazole-4-carboxaldehyde and some 2-arylthiazole-4-carboxaldehydes) was achieved by a simplified protocol of the published synthesis.